Metafora^®–SR

– Reducing the risk or delaying the onset of type 2 diabetes in adult patients who are overweight and have PTH* and/or PGN*, and/or elevated HbA1C levels, and who have:

• a high risk of developing overt (manifest) type 2 diabetes (see the “Pharmacodynamics” section);
• progressive carbohydrate metabolism disorders despite lifestyle modifications for 3 to 6 months.

Treatment with Metafora^®-SR should be based on a risk assessment that includes appropriate glycemic control measures and indications of high cardiovascular risk.

Lifestyle changes should be continued in parallel with the initiation of metformin, except in cases where the patient is unable to make such changes for medical reasons.

*IMT: Impaired glucose tolerance; IFG: Impaired fasting glucose.

– Treatment of type 2 diabetes in adults, particularly in overweight patients, when diet and exercise alone do not provide adequate glycemic control. The drug may be used as monotherapy or in combination with other oral antidiabetic agents, or in combination with insulin.